Vascular actions of angiotensin 1-7 in the human microcirculation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 6, 2016, Pages 1254-1262

  Durand, Matthew J ^a   Zinkevich, Natalya S ^a,b   Riedel, Michael ^a   Gutterman, David D ^a   Nasci, Victoria L ^a   Salato, Valerie K ^a   Hijjawi, John B ^a   Reuben, Charles F ^a   North, Paula E ^a   Beyer, Andreas M ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CARROLL UNIVERSITY   (United States)

Author keywords

coronary artery disease; microcirculation; nitric oxide; telomerase; vasodilation

Indexed keywords

ANGIOTENSIN[1-7]; CATALASE; HYDROGEN PEROXIDE; MACROGOL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TELOMERASE; TELOMERASE INHIBITOR; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; TERT PROTEIN, HUMAN; VASODILATOR AGENT;

ADIPOSE TISSUE; AGED; ARTERIOLE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MALE; MICROCIRCULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; VASODILATATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CELL CULTURE; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEART ATRIUM; IN VITRO STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ADIPOSE TISSUE; AGED; ANGIOTENSIN I; ARTERIOLES; CASE-CONTROL STUDIES; CELLS, CULTURED; CORONARY ARTERY DISEASE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FEMALE; HEART ATRIA; HUMANS; IN VITRO TECHNIQUES; MALE; MIDDLE AGED; NITRIC OXIDE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TELOMERASE; VASODILATION; VASODILATOR AGENTS;

EID: 84963556451     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307518     Document Type: Article

References (58)

1. Sasaki S, Higashi Y, Nakagawa K, Matsuura H, Kajiyama G, Oshima T, Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension 2001 38 90 94
2. Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, Brown NJ, Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension 2001 37 1136 1140
3. Liu Y, Zhao H, Li H, Kalyanaraman B, Nicolosi AC, Gutterman DD, Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ Res 2003 93 573 580. doi: 10.1161/01.RES.0000091261.19387.AE
4. Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gutterman DD, Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res 2003 92 e31 e40
5. Sato A, Sakuma I, Gutterman DD, Mechanism of dilation to reactive oxygen species in human coronary arterioles. Am J Physiol Heart Circ Physiol 2003 285 H2345 H2354. doi: 10.1152/ajpheart.00458.2003
6. Phillips SA, Hatoum OA, Gutterman DD, The mechanism of flow-induced dilation in human adipose arterioles involves hydrogen peroxide during CAD. Am J Physiol Heart Circ Physiol 2007 292 H93 H100. doi: 10.1152/ajpheart.00819.2006
7. Sullivan JC, Rodriguez-Miguelez P, Zimmerman MA, Harris RA, Differences in angiotensin (1-7) between men and women. Am J Physiol Heart Circ Physiol 2015 308 H1171 H1176. doi: 10.1152/ajpheart.00897.2014
8. Zhang Y, Liu J, Luo JY, Tian XY, Cheang WS, Xu J, Lau CW, Wang L, Wong WT, Wong CM, Lan HY, Yao X, Raizada MK, Huang Y, Upregulation of angiotensin (1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes. Antioxid Redox Signal 2015 23 880 892. doi: 10.1089/ars.2014.6070
9. Sharma NK, Reyes A, Green P, Caron MJ, Bonini MG, Gordon DM, Holt IJ, Santos JH, Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. Nucleic Acids Res 2012 40 712 725. doi: 10.1093/nar/gkr758
10. Mendelsohn AR, Larrick JW, Telomerase reverse transcriptase and peroxisome proliferator-activated receptor γ co-activator-1α cooperate to protect cells from DNA damage and mitochondrial dysfunction in vascular senescence. Rejuvenation Res 2015 18 479 483. doi: 10.1089/rej.2015.1780
11. Beyer AM, Freed JK, Durand MJ, Riedel M, Ait-Aissa K, Green P, Hockenberry JC, Morgan RG, Donato AJ, Peleg R, Gasparri M, Rokkas CK, Santos JH, Priel E, Gutterman DD, Critical role for telomerase in the mechanism of flow-mediated dilation in the human microcirculation. Circ Res 2016 118 856 866. doi: 10.1161/CIRCRESAHA.115.307918
12. Imanishi T, Hano T, Nishio I, Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005 23 97 104
13. Imanishi T, Kobayashi K, Kuroi A, Ikejima H, Akasaka T, Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell. Hypertens Res 2008 31 757 765. doi: 10.1291/hypres.31.757
14. Kobayashi K, Imanishi T, Akasaka T, Endothelial progenitor cell differentiation and senescence in an angiotensin II-infusion rat model. Hypertens Res 2006 29 449 455. doi: 10.1291/hypres.29.449
15. Merrill DC, Karoly M, Chen K, Ferrario CM, Brosnihan KB, Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 2002 18 239 245. doi: 10.1385/ENDO:18:3:239
16. Velloso EP, Vieira R, Cabral AC, Kalapothakis E, Santos RA, Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype. Braz J Med Biol Res 2007 40 583 590
17. Nussberger J, Brunner DB, Nyfeler JA, Linder L, Brunner HR, Measurement of immunoreactive angiotensin-(1-7) heptapeptide in human blood. Clin Chem 2001 47 726 729
18. Sullivan JC, Rodriguez-Miguelez P, Zimmerman MA, Harris RA, Differences in angiotensin (1-7) between men and women. Am J Physiol Heart Circ Physiol 2015 308 H1171 H1176. doi: 10.1152/ajpheart.00897.2014
19. Silva DM, Gomes-Filho A, Olivon VC, Santos TM, Becker LK, Santos RA, Lemos VS, Swimming training improves the vasodilator effect of angiotensin-(1-7) in the aorta of spontaneously hypertensive rat. J Appl Physiol (1985) 2011 111 1272 1277. doi: 10.1152/japplphysiol.00034.2011
20. Souza ÁP, Sobrinho DB, Almeida JF, Alves GM, Macedo LM, Porto JE, Vêncio EF, Colugnati DB, Santos RA, Ferreira AJ, Mendes EP, Castro CH, Angiotensin II type 1 receptor blockade restores angiotensin-(1-7)-induced coronary vasodilation in hypertrophic rat hearts. Clin Sci (Lond) 2013 125 449 459. doi: 10.1042/CS20120519
21. Freed JK, Beyer AM, LoGiudice JA, Hockenberry JC, Gutterman DD, Ceramide changes the mediator of flow-induced vasodilation from nitric oxide to hydrogen peroxide in the human microcirculation. Circ Res 2014 115 525 532. doi: 10.1161/CIRCRESAHA.115.303881
22. Dranka BP, Hill BG, Darley-Usmar VM, Mitochondrial reserve capacity in endothelial cells: the impact of nitric oxide and reactive oxygen species. Free Radic Biol Med 2010 48 905 914. doi: 10.1016/j.freeradbiomed.2010.01.015
23. Clementi E, Brown GC, Foxwell N, Moncada S, On the mechanism by which vascular endothelial cells regulate their oxygen consumption. Proc Natl Acad Sci USA 1999 96 1559 1562
24. Paxinou E, Weisse M, Chen Q, Souza JM, Hertkorn C, Selak M, Daikhin E, Yudkoff M, Sowa G, Sessa WC, Ischiropoulos H, Dynamic regulation of metabolism and respiration by endogenously produced nitric oxide protects against oxidative stress. Proc Natl Acad Sci USA 2001 98 11575 11580. doi: 10.1073/pnas.201293198
25. Phatak P, Burger AM, Telomerase and its potential for therapeutic intervention. Br J Pharmacol 2007 152 1003 1011. doi: 10.1038/sj.bjp.0707374
26. Damm K, Hemmann U, Garin-Chesa P, A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001 20 6958 6968. doi: 10.1093/emboj/20.24.6958
27. Zisman LS, Meixell GE, Bristow MR, Canver CC, Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation 2003 108 1679 1681. doi: 10.1161/01.CIR.0000094733.61689.D4
28. Lawrence AC, Clark IJ, Campbell DJ, Increased angiotensin-(1-7) in hypophysial-portal plasma of conscious sheep. Neuroendocrinology 1992 55 105 114
29. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ, Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991 18 763 773
30. Kohara K, Brosnihan KB, Chappell MC, Khosla MC, Ferrario CM, Angiotensin-(1-7). A member of circulating angiotensin peptides. Hypertension 1991 17 131 138
31. Kohara K, Brosnihan KB, Ferrario CM, Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides 1993 14 883 891
32. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM, Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996 14 1380 1381
33. Durand MJ, Raffai G, Weinberg BD, Lombard JH, Angiotensin-(1-7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries. Am J Physiol Heart Circ Physiol 2010 299 H1024 H1033. doi: 10.1152/ajpheart.00328.2010
34. Raffai G, Durand MJ, Lombard JH, Acute and chronic angiotensin-(1-7) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J Physiol Heart Circ Physiol 2011 301 H1341 H1352. doi: 10.1152/ajpheart.00202.2011
35. Walters PE, Gaspari TA, Widdop RE, Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005 45 960 966. doi: 10.1161/01.HYP.0000160325.59323.b8
36. Rowe BP, Saylor DL, Speth RC, Absher DR, Angiotensin-(1-7) binding at angiotensin II receptors in the rat brain. Regul Pept 1995 56 139 146
37. Bouley R, Pérodin J, Plante H, Rihakova L, Bernier SG, Maletínská L, Guillemette G, Escher E, N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor. Eur J Pharmacol 1998 343 323 331
38. Neves LA, Averill DB, Ferrario CM, Chappell MC, Aschner JL, Walkup MP, Brosnihan KB, Characterization of angiotensin-(1-7) receptor subtype in mesenteric arteries. Peptides 2003 24 455 462
39. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP, Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 2005 46 937 942. doi: 10.1161/01.HYP.0000175813.04375.8a
40. Vasa M, Breitschopf K, Zeiher AM, Dimmeler S, Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res 2000 87 540 542
41. Farsetti A, Grasselli A, Bacchetti S, Gaetano C, Capogrossi MC, The telomerase tale in vascular aging: regulation by estrogens and nitric oxide signaling. J Appl Physiol (1985) 2009 106 333 337. doi: 10.1152/japplphysiol.91360.2008
42. Spyridopoulos I, Is telomerase a potential target for vascular rejuvenation? Atherosclerosis 2011 216 19 20. doi: 10.1016/j.atherosclerosis.2011.02.015
43. Goya K, Sumitani S, Otsuki M, Xu X, Yamamoto H, Kurebayashi S, Saito H, Kouhara H, Kasayama S, The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J Diabetes Complications 2006 20 336 342. doi: 10.1016/j.jdiacomp.2005.08.003
44. Cho DH, Choi YJ, Jo SA, Jo I, Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem 2004 279 2499 2506. doi: 10.1074/jbc.M309451200
45. Rizza S, Cardellini M, Porzio O, Pecchioli C, Savo A, Cardolini I, Senese N, Lauro D, Sbraccia P, Lauro R, Federici M, Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects. Atherosclerosis 2011 215 180 183. doi: 10.1016/j.atherosclerosis.2010.12.021
46. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ, Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005 46 773 778
47. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T, Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005 45 1925 1931. doi: 10.1016/j.jacc.2005.03.041
48. Rashid-Kolvear F, Taboski MA, Nguyen J, Wang DY, Harrington LA, Done SJ, Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer 2010 10 390. doi: 10.1186/1471-2407-10-390
49. Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, Menegatti E, Daniela B, Minelli R, Giglioni B, Dianzani MU, Ferretti C, Barrera G, PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network in colon cancer cells. J Cell Mol Med 2010 14 6A 1347 1357. doi: 10.1111/j.1582-4934.2009.00966.x
50. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, Stone JF, Berger JP, Law RE, Bruemmer D, Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ Res 2006 98 e50 e59. doi: 10.1161/01.RES.0000218271.93076.c3
51. Dhaunsi GS, Yousif MH, Akhtar S, Chappell MC, Diz DI, Benter IF, Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities. Eur J Pharmacol 2010 638 108 114. doi: 10.1016/j.ejphar.2010.04.030
52. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R, Direct activation of TERT transcription by c-MYC. Nat Genet 1999 21 220 224. doi: 10.1038/6010
53. Hoffmeyer K, Raggioli A, Rudloff S, Anton R, Hierholzer A, Del Valle I, Hein K, Vogt R, Kemler R, Wnt/β-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012 336 1549 1554. doi: 10.1126/science.1218370
54. Zhou J, Dai W, Song J, miR-1182 inhibits growth and mediates the chemosensitivity of bladder cancer by targeting hTERT. Biochem Biophys Res Commun 2016 470 445 452. doi: 10.1016/j.bbrc.2016.01.014
55. Cheng D, Zhao Y, Wang S, Jia W, Kang J, Zhu J, Human telomerase reverse transcriptase (hTERT) transcription requires Sp1/Sp3 binding to the promoter and a permissive chromatin environment. J Biol Chem 2015 290 30193 30203. doi: 10.1074/jbc.M115.662221
56. Akincilar SC, Unal B, Tergaonkar V, Reactivation of telomerase in cancer. Cell Mol Life Sci 2016 73 1659 1670. doi: 10.1007/s00018-016-2146-9
57. Faria-Silva R, Duarte FV, Santos RA, Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 2005 46 948 952. doi: 10.1161/01.HYP.0000174594.17052.33
58. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A, Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 2002 277 15566 15572. doi: 10.1074/jbc.M201266200